Whalesbook
Advanced Enzyme Technologies Ltd. has detailed its audited financial results for the fiscal year ended March 31, 2026, confirming significant year-on-year growth across its operations. The company announced that consolidated net profit rose 29.6% to ₹173.6 crore (₹1,736.08 million), driven by a 17% increase in consolidated revenue to ₹745.7 crore (₹7,457.57 million).
Its standalone performance also showed robust gains. Standalone net profit climbed 28.7% to ₹131.8 crore (₹1,318.06 million), supported by a 28.8% rise in standalone revenue to ₹452.7 crore (₹4,527.66 million).
The Board of Directors has recommended a final dividend of ₹1.35 per equity share for FY26, pending shareholder approval at the upcoming Annual General Meeting (AGM). Notably, the company decided to defer declaring an interim dividend. This move aims to preserve capital for potential strategic actions, signalling a focus on future growth initiatives or acquisitions.
Key governance matters were also addressed during the reporting period. Mr. Mukund Madhusudan Kabra was reappointed as Whole Time Director, and Mr. Pradip Bhailal Shah was appointed as an Additional Director (Independent). MSKA & Associates LLP was reappointed as the Statutory Auditors for a second five-year term, ensuring leadership continuity and operational stability.
Investor Significance: Growth and Strategy
This strong financial performance highlights Advanced Enzyme's capacity to meet market demand for its enzyme and probiotic solutions. The proposed final dividend offers a direct return to shareholders. Simultaneously, the strategic decision to retain capital by deferring an interim dividend signals a disciplined approach to capital allocation, positioning the company for potential future expansion. The continuity in leadership and auditing through director reappointments and auditor reselection provides confidence in the company's ongoing operations and strategic direction.
Company Background: Recovery and Market Position
Advanced Enzyme Technologies is a leading global provider of specialty enzymes and probiotics. The company has expanded its international reach, particularly in the US and Europe, supported by ongoing investment in research and development for specialized applications. Following adjustments in supply chains and input costs in FY23, the company has shown a strong recovery trend since FY24, building momentum into FY26. This resurgence aligns with increasing global demand for sustainable, bio-based solutions.
Market Trends: Peer Performance
Globally, major enzyme companies like Novonesis are also experiencing robust growth, driven by similar demands for sustainable, bio-based products across various industries. Advanced Enzyme's performance mirrors this broader market trend.
Shareholder Actions and Future Outlook
Shareholders will vote on the recommended final dividend and director reappointments/appointments at the upcoming AGM. The company's enhanced financial flexibility, achieved by retaining capital, places it in a strong position for potential strategic initiatives that could shape its future growth trajectory. Investors will be watching for formal announcements regarding the dividend record date and AGM details. Further insights will come from management commentary on the 'strategic actions' planned for the preserved capital, as well as future quarterly results indicating continued growth drivers.